EAN 2020 | HER-MES study: erenumab versus topiramate in episodic migraine

Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, outlines the characteristics of the HER-MES study (NCT03828539), the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).